Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Ion Beam Applications SA (IOBCF)

Compare
11.80
0.00
(0.00%)
At close: April 3 at 4:00:00 PM EDT
Loading Chart for IOBCF
  • Previous Close 0.00
  • Open 14.05
  • Bid 11.07 x 21500
  • Ask 11.80 x 40000
  • Day's Range 14.05 - 14.05
  • 52 Week Range 11.80 - 15.75
  • Volume 100
  • Avg. Volume 313
  • Market Cap (intraday) 358.119M
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 40.69
  • EPS (TTM) 0.29
  • Earnings Date May 22, 2025
  • Forward Dividend & Yield 0.18 (1.54%)
  • Ex-Dividend Date Jun 27, 2024
  • 1y Target Est --

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

www.iba-worldwide.com

1,943

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IOBCF

View More

Performance Overview: IOBCF

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

IOBCF
15.71%
BEL 20 (^BFX)
1.63%

1-Year Return

IOBCF
11.51%
BEL 20 (^BFX)
11.37%

3-Year Return

IOBCF
41.45%
BEL 20 (^BFX)
2.26%

5-Year Return

IOBCF
62.79%
BEL 20 (^BFX)
50.32%

Compare To: IOBCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IOBCF

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    348.34M

  • Enterprise Value

    347.84M

  • Trailing P/E

    40.40

  • Forward P/E

    10.21

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.70

  • Price/Book (mrq)

    3.61

  • Enterprise Value/Revenue

    0.69

  • Enterprise Value/EBITDA

    11.84

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.69%

  • Return on Assets (ttm)

    2.63%

  • Return on Equity (ttm)

    8.86%

  • Revenue (ttm)

    465.75M

  • Net Income Avi to Common (ttm)

    7.85M

  • Diluted EPS (ttm)

    0.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    60.44M

  • Total Debt/Equity (mrq)

    66.44%

  • Levered Free Cash Flow (ttm)

    -23.88M

Research Analysis: IOBCF

View More

Company Insights: IOBCF

Research Reports: IOBCF

View More

People Also Watch